Pub Date : 2024-12-01DOI: 10.1016/j.cson.2024.100066
Cansu Şentürk , Evin Korkmaz
Introduction
This study was planned to investigate in-depth patients' experiences with dumping syndrome after total gastrectomy and their self-management in this condition.
Method
The research was conducted in a qualitative study design. Data were collected using a face-to-face interview method with patients who underwent total gastrectomy surgery in 2023, using a voice recorder when they came to their outpatient clinic appointments. The interviews were completed in 20–40 min. The MAXQDA program was used to analyze the data obtained. The Consolidated Criteria for Reporting Qualitative Research (COREQ) was used as a guide for reporting this study.
Results
The study included ten patients who underwent total gastrectomy surgery. The mean age of the patients was 45 years and above. 70% of the patients were male and 30% were female. During the interview with the patients, six main themes and twenty-five sub-themes were formed: 1- Regret about the surgery, 2- Dietary recommendations, 3-Time of complaints, 4- Dietary pattern, 5- What was done for postprandial complaints, 6- Complaints after eating.
Conclusion
It is thought that an integrated team-based approach to postoperative care is necessary for patients to gain self-management skills.
{"title":"Patients who have undergone total gastrectomy investigation of self-management experiences on dumping syndrome","authors":"Cansu Şentürk , Evin Korkmaz","doi":"10.1016/j.cson.2024.100066","DOIUrl":"10.1016/j.cson.2024.100066","url":null,"abstract":"<div><h3>Introduction</h3><div>This study was planned to investigate in-depth patients' experiences with dumping syndrome after total gastrectomy and their self-management in this condition.</div></div><div><h3>Method</h3><div>The research was conducted in a qualitative study design. Data were collected using a face-to-face interview method with patients who underwent total gastrectomy surgery in 2023, using a voice recorder when they came to their outpatient clinic appointments. The interviews were completed in 20–40 min. The MAXQDA program was used to analyze the data obtained. The Consolidated Criteria for Reporting Qualitative Research (COREQ) was used as a guide for reporting this study.</div></div><div><h3>Results</h3><div>The study included ten patients who underwent total gastrectomy surgery. The mean age of the patients was 45 years and above. 70% of the patients were male and 30% were female. During the interview with the patients, six main themes and twenty-five sub-themes were formed: 1- Regret about the surgery, 2- Dietary recommendations, 3-Time of complaints, 4- Dietary pattern, 5- What was done for postprandial complaints, 6- Complaints after eating.</div></div><div><h3>Conclusion</h3><div>It is thought that an integrated team-based approach to postoperative care is necessary for patients to gain self-management skills.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 4","pages":"Article 100066"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.cson.2024.100068
Meseret Jeldu, Abraham Fessehaye Sium, Bethel Dereje
Objective
To describe clinical characteristics and treatment outcomes of vulvar cancer patients managed at a gynecologic oncology treatment center in Ethiopia.
Methods and materials
This was a 6-year review of vulvar cancers patients (with and without HIV co-infection) that were managed at St. Paul’s Hospital Millennium Medical College (Ethiopia) between 2017 and 2022. Data were extracted from patient’s medical records using a data extraction tool. Data were analyzed using SPSS version 26. Simple descriptive statistics and Chi-squared test were carried out as appropriate.
Results
After excluding 10 patients for incomplete data, a total of 96 patients were included in the final analysis, out of which 65(67.7%) patients had HIV co-infection. Surgery with or without chemotherapy was the most common (62/96, 64.8%) treatment modality provided for the patients while the remaining 34 patients were treated with primary chemoradiation. Among those who had surgery, the majority of them (43/62, 69.4%) were managed with surgery alone, followed by another 16(25.8%) patients who were treated with neoadjuvant chemotherapy followed by surgery.
Conclusion
In this study, most vulvar cancer patients (more than three-quarters) had favorable survival outcomes at a median follow-up of 3 years post-standard treatment for vulvar cancer.
{"title":"Clinical characteristics and treatment outcomes of Vulvar cancer patients at a tertiary setting in Ethiopia: A 6-year review","authors":"Meseret Jeldu, Abraham Fessehaye Sium, Bethel Dereje","doi":"10.1016/j.cson.2024.100068","DOIUrl":"10.1016/j.cson.2024.100068","url":null,"abstract":"<div><h3>Objective</h3><div>To describe clinical characteristics and treatment outcomes of vulvar cancer patients managed at a gynecologic oncology treatment center in Ethiopia.</div></div><div><h3>Methods and materials</h3><div>This was a 6-year review of vulvar cancers patients (with and without HIV co-infection) that were managed at St. Paul’s Hospital Millennium Medical College (Ethiopia) between 2017 and 2022. Data were extracted from patient’s medical records using a data extraction tool. Data were analyzed using SPSS version 26. Simple descriptive statistics and Chi-squared test were carried out as appropriate.</div></div><div><h3>Results</h3><div>After excluding 10 patients for incomplete data, a total of 96 patients were included in the final analysis, out of which 65(67.7%) patients had HIV co-infection. Surgery with or without chemotherapy was the most common (62/96, 64.8%) treatment modality provided for the patients while the remaining 34 patients were treated with primary chemoradiation. Among those who had surgery, the majority of them (43/62, 69.4%) were managed with surgery alone, followed by another 16(25.8%) patients who were treated with neoadjuvant chemotherapy followed by surgery.</div></div><div><h3>Conclusion</h3><div>In this study, most vulvar cancer patients (more than three-quarters) had favorable survival outcomes at a median follow-up of 3 years post-standard treatment for vulvar cancer.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 4","pages":"Article 100068"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.cson.2024.100069
Shangshang Ma , Kun Li , Rangrang Wang , Jiayi Qian , Yongfei Fan , Xichun Qin , Mingjun Li , Leilei Wu
Background
Adjuvant chemotherapy (ACT) remains the current first-line systemic treatment option for patients with KRAS-mutated lung adenocarcinoma (LUAD), but the response is not effective. The prognosis of ACT in patients with KRAS mutations in stage I LUAD has not yet been effectively explored.
Methods
Detailed data about patients with stage I LUAD from Shanghai Pulmonary Hospital were collected in this ambispective study. Pearson's Chi-square test, Kaplan-Meier analysis, and Cox proportional hazard models were performed in this study. The primary observational endpoint was overall survival (OS). Sensitivity analysis was performed to assess the robustness of the findings.
Results
In this study population, 10.87% (194 out of 1783) of stage I LUAD patients possessed KRAS mutations. In the KRAS-mutated cohort, 7 patients harbored EGFR L858R point mutation, 2 patients exhibited EGFR exon 19 Del mutation, 2 patients had ALK rearrangement, and 1 patient for other EGFR mutations. Patients harboring KRAS mutations had a worse OS compared to KRAS wild-type (WT) patients (5-year OS rate: 96% vs. 82%, P < 0.001). In addition, the KARS(G12C) mutation was an independent factor for poor prognosis (P < 0.001). Importantly, ACT improved survival in patients with stage IB LUAD (P = 0.02) while not improved survival in the group of stage IB patients with KRAS mutations (P = 0.31).
Conclusions
KRAS mutation could co-occur with EGFR mutation and ALK rearrangement. KRAS mutation was associated with poor prognosis in stage I LUAD patients. In addition, ACT did not improve prognosis in stage IB LUAD patients with KRAS mutations. Our findings require more research to be confirmed.
{"title":"The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma","authors":"Shangshang Ma , Kun Li , Rangrang Wang , Jiayi Qian , Yongfei Fan , Xichun Qin , Mingjun Li , Leilei Wu","doi":"10.1016/j.cson.2024.100069","DOIUrl":"10.1016/j.cson.2024.100069","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant chemotherapy (ACT) remains the current first-line systemic treatment option for patients with <em>KRAS</em>-mutated lung adenocarcinoma (LUAD), but the response is not effective. The prognosis of ACT in patients with <em>KRAS</em> mutations in stage I LUAD has not yet been effectively explored.</div></div><div><h3>Methods</h3><div>Detailed data about patients with stage I LUAD from Shanghai Pulmonary Hospital were collected in this ambispective study. Pearson's Chi-square test, Kaplan-Meier analysis, and Cox proportional hazard models were performed in this study. The primary observational endpoint was overall survival (OS). Sensitivity analysis was performed to assess the robustness of the findings.</div></div><div><h3>Results</h3><div>In this study population, 10.87% (194 out of 1783) of stage I LUAD patients possessed <em>KRAS</em> mutations. In the <em>KRAS</em>-mutated cohort, 7 patients harbored <em>EGFR L858R</em> point mutation, 2 patients exhibited <em>EGFR exon 19 Del</em> mutation, 2 patients had <em>ALK</em> rearrangement, and 1 patient for other <em>EGFR</em> mutations. Patients harboring <em>KRAS</em> mutations had a worse OS compared to <em>KRAS</em> wild-type (WT) patients (5-year OS rate: 96% <em>vs.</em> 82%, <em>P</em> < 0.001). In addition, the <em>KARS(G12C)</em> mutation was an independent factor for poor prognosis (<em>P</em> < 0.001). Importantly, ACT improved survival in patients with stage IB LUAD (<em>P</em> = 0.02) while not improved survival in the group of stage IB patients with <em>KRAS</em> mutations (<em>P</em> = 0.31).</div></div><div><h3>Conclusions</h3><div><em>KRAS</em> mutation could co-occur with <em>EGFR</em> mutation and <em>ALK</em> rearrangement. <em>KRAS</em> mutation was associated with poor prognosis in stage I LUAD patients. In addition, ACT did not improve prognosis in stage IB LUAD patients with <em>KRAS</em> mutations. Our findings require more research to be confirmed.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 4","pages":"Article 100069"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.cson.2024.100067
Zhang Fang
Objective
To explore the expression of p53 protein in cancer tissue of breast cancer, analyze the relationship between positive rate of expression of p53 protein and axillary lymph node status.
Method
137 breast cancer patients in general hospital of PLA from June 2023 to October 2023 were selected and divided into axillary lymph node metastasis group and non-axillary lymph node metastasis group according to routine pathological outcome after surgery. Detect the situation of expression of p53 protein in cancer tissue using immunohistochemical method. The rate of expression of p53 protein between axillary lymph node metastasis group and non-axillary lymph node metastasis group were compared by χ2 test. At the same time, the relationship between the expression of p53 protein in breast cancer tissue and the age, the longest tumor diameter and tumor TNM stage was analyzed.
Result
The rate of expression of p53 protein was 60.78%, 43.02% in the axillary lymph node metastasis group and non-axillary lymph node metastasis group respectively. The difference was statistically significant (χ2 = 4.040, P = 0.044＜0.05). The expression of p53 protein in breast cancer tissue was of no relationship with age (P = 0.945＞0.05),the longest tumor diameter (P = 0.200＞0.05) and tumor TNM stage (P = 0.300 > 0.05).
Conclusion
There was a close relationship between expression of p53 protein in breast cancer tissue and axillary lymph node metastasis, and it can be regard as a predictive factor in the axillary lymph node status.
{"title":"Relationship between expression of p53 protein in breast cancer and axillary lymph node metastasis","authors":"Zhang Fang","doi":"10.1016/j.cson.2024.100067","DOIUrl":"10.1016/j.cson.2024.100067","url":null,"abstract":"<div><h3>Objective</h3><div>To explore the expression of p53 protein in cancer tissue of breast cancer, analyze the relationship between positive rate of expression of p53 protein and axillary lymph node status.</div></div><div><h3>Method</h3><div>137 breast cancer patients in general hospital of PLA from June 2023 to October 2023 were selected and divided into axillary lymph node metastasis group and non-axillary lymph node metastasis group according to routine pathological outcome after surgery. Detect the situation of expression of p53 protein in cancer tissue using immunohistochemical method. The rate of expression of p53 protein between axillary lymph node metastasis group and non-axillary lymph node metastasis group were compared by χ2 test. At the same time, the relationship between the expression of p53 protein in breast cancer tissue and the age, the longest tumor diameter and tumor TNM stage was analyzed.</div></div><div><h3>Result</h3><div>The rate of expression of p53 protein was 60.78%, 43.02% in the axillary lymph node metastasis group and non-axillary lymph node metastasis group respectively. The difference was statistically significant (χ2 = 4.040, P = 0.044＜0.05). The expression of p53 protein in breast cancer tissue was of no relationship with age (P = 0.945＞0.05),the longest tumor diameter (P = 0.200＞0.05) and tumor TNM stage (P = 0.300 > 0.05).</div></div><div><h3>Conclusion</h3><div>There was a close relationship between expression of p53 protein in breast cancer tissue and axillary lymph node metastasis, and it can be regard as a predictive factor in the axillary lymph node status.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 4","pages":"Article 100067"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.cson.2024.100060
Emmanuel Zappettini
{"title":"Global disparities in surgical oncology: Bridging the gap in cancer care a challenge to overcome","authors":"Emmanuel Zappettini","doi":"10.1016/j.cson.2024.100060","DOIUrl":"10.1016/j.cson.2024.100060","url":null,"abstract":"","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 4","pages":"Article 100060"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-20DOI: 10.1016/j.cson.2024.100064
Bhawani Pathak , Rajender Kumar Karwasra
Background
Preoperative assessment of breast features is indispensable for both cosmetic and reconstructive breast surgical procedures. In this study we aim to investigate the effect of breast ptosis on breast volume estimation by various methods.
Methods
Fifty patients of breast cancer planned for modified radical mastectomy were taken up. Preoperatively breast anthropometric measurement taken, grade of ptosis was noted and breast volume was calculated by anthropometry and mammography and intraopratively mastectomy specimen weight and volume was recorded. Breast volume calculated by mammography and anthropometry compared with mastectomy specimen volume and weight and correlation with ptosis was statistically analyzed.
Results
Mastectomy specimen volume showed best agreement with mastectomy specimen weight (r = .993, <.001), followed by mammographic method (r = .985, P < .001), anthropometry by breast circumference in supine method (r = .982, P < .001), anthropometry by breast circumference in upright method (r = .979, P < .001) and anthropometry by breast radius and mammary projection method (r = .969, P < .001).
Conclusion
Mammography is simple, cost effective and most accurate method for breast volume estimation followed by anthropometric breast volume calculation. As size of breast and grade of breast ptosis increases the accuracy of all methods of breast volume estimation decreases.
{"title":"Correlation of weight and volume of modified radical mastectomy specimen with ptosis of breast in patients of breast cancer","authors":"Bhawani Pathak , Rajender Kumar Karwasra","doi":"10.1016/j.cson.2024.100064","DOIUrl":"10.1016/j.cson.2024.100064","url":null,"abstract":"<div><h3>Background</h3><div>Preoperative assessment of breast features is indispensable for both cosmetic and reconstructive breast surgical procedures. In this study we aim to investigate the effect of breast ptosis on breast volume estimation by various methods.</div></div><div><h3>Methods</h3><div>Fifty patients of breast cancer planned for modified radical mastectomy were taken up. Preoperatively breast anthropometric measurement taken, grade of ptosis was noted and breast volume was calculated by anthropometry and mammography and intraopratively mastectomy specimen weight and volume was recorded. Breast volume calculated by mammography and anthropometry compared with mastectomy specimen volume and weight and correlation with ptosis was statistically analyzed.</div></div><div><h3>Results</h3><div>Mastectomy specimen volume showed best agreement with mastectomy specimen weight (r = .993, <.001), followed by mammographic method (r = .985, P < .001), anthropometry by breast circumference in supine method (r = .982, P < .001), anthropometry by breast circumference in upright method (r = .979, P < .001) and anthropometry by breast radius and mammary projection method (r = .969, P < .001).</div></div><div><h3>Conclusion</h3><div>Mammography is simple, cost effective and most accurate method for breast volume estimation followed by anthropometric breast volume calculation. As size of breast and grade of breast ptosis increases the accuracy of all methods of breast volume estimation decreases.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 4","pages":"Article 100064"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142720448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-19DOI: 10.1016/j.cson.2024.100065
Md Ismail Gazi , Mohammad Salauddin Mia , Mohammad Emrul Hasan Khan
In October 2023, the first laparoscopic pancreaticoduodenectomy (LPD) operation was successfully conducted in Bangladesh. This case study reported the surgical technique and outcomes of Bangladesh's first LPD procedure. The patient was a 55-year-old male patient with the diagnosis of periampullary carcinoma. He underwent a classical LPD lasting 360 min with a blood loss of 170 ml. Postoperatively, he experienced no major complications such as pancreatic fistula or bile leakage but developed atelectasis, which was managed effectively. His postoperative pain, assessed on a scale from 0 to 5, significantly reduced from day 3 (score 3) to day 7 (score 1). Histological examination confirmed adenocarcinoma at the ampullary site, with an R0 resection margin achieved. Sixteen lymph nodes were retrieved, none of which showed involvement. His hospital stay was 10 days, and he returned to work 14 days post-discharge. This operation marks a significant milestone in advancing surgical practices in Bangladesh. The successful completion of the first LPD in Bangladesh demonstrated the procedure's feasibility, safety, and potential benefits in a similar resource-limited setting.
{"title":"First successful laparoscopic pancreaticoduodenectomy in Bangladesh: Surgical procedure and operation outcome","authors":"Md Ismail Gazi , Mohammad Salauddin Mia , Mohammad Emrul Hasan Khan","doi":"10.1016/j.cson.2024.100065","DOIUrl":"10.1016/j.cson.2024.100065","url":null,"abstract":"<div><div>In October 2023, the first laparoscopic pancreaticoduodenectomy (LPD) operation was successfully conducted in Bangladesh. This case study reported the surgical technique and outcomes of Bangladesh's first LPD procedure. The patient was a 55-year-old male patient with the diagnosis of periampullary carcinoma. He underwent a classical LPD lasting 360 min with a blood loss of 170 ml. Postoperatively, he experienced no major complications such as pancreatic fistula or bile leakage but developed atelectasis, which was managed effectively. His postoperative pain, assessed on a scale from 0 to 5, significantly reduced from day 3 (score 3) to day 7 (score 1). Histological examination confirmed adenocarcinoma at the ampullary site, with an R0 resection margin achieved. Sixteen lymph nodes were retrieved, none of which showed involvement. His hospital stay was 10 days, and he returned to work 14 days post-discharge. This operation marks a significant milestone in advancing surgical practices in Bangladesh. The successful completion of the first LPD in Bangladesh demonstrated the procedure's feasibility, safety, and potential benefits in a similar resource-limited setting.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 4","pages":"Article 100065"},"PeriodicalIF":0.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01DOI: 10.1016/j.cson.2024.100057
I-Chin Lee , Björn-Ole Stüben , Mohammad Fard-Aghaie , Anastasios Giannou , Tarik Ghadban , Asmus Heumann , Jun Li
Perihilar cholangiocarcinoma, a formidable adversary in the field of hepatobiliary surgery, presents multifaceted challenges. This paper reviews its historical context, classification criteria, and regional variations in definition. It emphasizes the critical role of preoperative assessment, including hepatic hilum anatomy, biliary infiltration characteristics, and residual liver volume evaluation. The impact of the Bismuth-Corlette classification on surgical approach selection is elucidated, providing insights into tailored surgical options for each subtype based on the authors’ center experience in the last ten years. The article also touches upon laparoscopic and robotic surgery potential, underscoring the need for further research in this domain. Finally, it explores the potential role of liver transplantation as a treatment option for select patients ineligible for conventional surgery.
{"title":"Individualized surgical approach based on Bismuth-Corlette classification for perihilar cholangiocarcinoma","authors":"I-Chin Lee , Björn-Ole Stüben , Mohammad Fard-Aghaie , Anastasios Giannou , Tarik Ghadban , Asmus Heumann , Jun Li","doi":"10.1016/j.cson.2024.100057","DOIUrl":"10.1016/j.cson.2024.100057","url":null,"abstract":"<div><p>Perihilar cholangiocarcinoma, a formidable adversary in the field of hepatobiliary surgery, presents multifaceted challenges. This paper reviews its historical context, classification criteria, and regional variations in definition. It emphasizes the critical role of preoperative assessment, including hepatic hilum anatomy, biliary infiltration characteristics, and residual liver volume evaluation. The impact of the Bismuth-Corlette classification on surgical approach selection is elucidated, providing insights into tailored surgical options for each subtype based on the authors’ center experience in the last ten years. The article also touches upon laparoscopic and robotic surgery potential, underscoring the need for further research in this domain. Finally, it explores the potential role of liver transplantation as a treatment option for select patients ineligible for conventional surgery.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 3","pages":"Article 100057"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X24000254/pdfft?md5=6d80f38e00063e26d79cf9abf67d9bf0&pid=1-s2.0-S2773160X24000254-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142149577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01DOI: 10.1016/j.cson.2024.100056
Zhexue Wang , Junge Bai , Dedi Jiang , Yuegang Li , Xiyue Hu , Sergey Efetov , Yu Cao , Cuneyt Kayaalp , Audrius Dulskas , Darcy Shaw , Ming Yang , Zheng Liu , Xishan Wang
Colorectal cancer (CRC) is a global health concern, ranking among the leading causes of cancer-related mortality. This review critically evaluates the role of liquid biopsy in detecting minimal residual disease (MRD) in CRC. The increasing incidence, particularly in China, highlights the urgency of innovative approaches for early prediction of recurrence and metastasis. The importance of MRD should be underscored as residual tumor cells post-treatment significantly impact patient prognosis. Liquid biopsy methods, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and circulating tumor RNA, are dissected for their potential in identifying molecular markers associated with CRC. The focus on ctDNA highlights its non-invasive nature, real-time monitoring capabilities, and superiority over traditional detection methods in terms of sensitivity and timeliness. The review also delves into the limitations, such as clonal hematopoiesis and the critical consideration of optimal timing for postoperative ctDNA detection. In conclusion, the review highlights the significant potential of liquid biopsy, particularly ctDNA, as a dynamic and non-invasive tool for MRD detection in CRC. By complementing traditional methods, liquid biopsy contributes to precision in tumor research and personalized treatment. These advancements offer promising avenues for improving CRC patient prognosis and tailoring individualized treatment strategies.
{"title":"Liquid biopsy for monitoring minimal residual disease in colorectal cancer: A promising approach with clinical implications","authors":"Zhexue Wang , Junge Bai , Dedi Jiang , Yuegang Li , Xiyue Hu , Sergey Efetov , Yu Cao , Cuneyt Kayaalp , Audrius Dulskas , Darcy Shaw , Ming Yang , Zheng Liu , Xishan Wang","doi":"10.1016/j.cson.2024.100056","DOIUrl":"10.1016/j.cson.2024.100056","url":null,"abstract":"<div><p>Colorectal cancer (CRC) is a global health concern, ranking among the leading causes of cancer-related mortality. This review critically evaluates the role of liquid biopsy in detecting minimal residual disease (MRD) in CRC. The increasing incidence, particularly in China, highlights the urgency of innovative approaches for early prediction of recurrence and metastasis. The importance of MRD should be underscored as residual tumor cells post-treatment significantly impact patient prognosis. Liquid biopsy methods, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and circulating tumor RNA, are dissected for their potential in identifying molecular markers associated with CRC. The focus on ctDNA highlights its non-invasive nature, real-time monitoring capabilities, and superiority over traditional detection methods in terms of sensitivity and timeliness. The review also delves into the limitations, such as clonal hematopoiesis and the critical consideration of optimal timing for postoperative ctDNA detection. In conclusion, the review highlights the significant potential of liquid biopsy, particularly ctDNA, as a dynamic and non-invasive tool for MRD detection in CRC. By complementing traditional methods, liquid biopsy contributes to precision in tumor research and personalized treatment. These advancements offer promising avenues for improving CRC patient prognosis and tailoring individualized treatment strategies.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 3","pages":"Article 100056"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X24000242/pdfft?md5=7deada45477b79742f5dd072adc52c92&pid=1-s2.0-S2773160X24000242-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142149578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01DOI: 10.1016/j.cson.2024.100055
Mark Alexander Taylor
{"title":"Surgical frontiers in metastatic disease: Shaping cancer care","authors":"Mark Alexander Taylor","doi":"10.1016/j.cson.2024.100055","DOIUrl":"10.1016/j.cson.2024.100055","url":null,"abstract":"","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 3","pages":"Article 100055"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X24000230/pdfft?md5=c54e844c551ffe0fc5feb7e4e95c9213&pid=1-s2.0-S2773160X24000230-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号